1. When should decision-analytic modeling be used in the economic evaluation of health care?

   • Uwe Siebert MDH, MPH

   Editorial Pages: 143 - 150

2. Pharmaceutical expenditure in Spain: evolution and cost containment measures during 1998–2001

   • Josep Darbà

   Original Papers Pages: 151 - 157

3. A fuzzy logic approach toward solving the analytic enigma of health system financing

   • Dov Chernichovsky
   • Arkady Bolotin
   • David de Leeuw

   Original Papers Pages: 158 - 175

   

4. Scale of reference bias and the evolution of health

   • Wim Groot

   Original Papers Pages: 176 - 183

5. Is therapeutic innovation responsible for the increase in drug expenditure?

   • Philippe Cavalié

   Original Papers Pages: 184 - 194

   

6. Time to disable DALYs?

   • Carl Hampus Lyttkens

   Original Papers 01 July 2003 Pages: 195 - 202

   

7. Costs and effectiveness of a syringe distribution and needle exchange program for HIV prevention in a regional setting

   • Juan M. Cabasés
   • Eduardo Sánchez

   Original Papers 01 July 2003 Pages: 203 - 208

   

8. Economic evaluation of human papillomavirus screening in Germany

   • T. Mittendorf
   • K. U. Petry
   • J. M. von der Schulenburg

   Original Papers Pages: 209 - 215

   

9. Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK

   • Mike Aristides
   • Michael Lees
   • Nikos Maniadakis

   Original Papers 01 July 2003 Pages: 216 - 221

   

10. A single European currency for EQ-5D health states

    • Wolfgang Greiner
    • Tom Weijnen
    • Frank de Charro

    Original papers Pages: 222 - 231

    

11. The efficiency of treatment strategies of general practitioners

    • Matthias Staat

    Congress Papers Pages: 232 - 238

    

12. Commentary on Coyle et al., "The assessment of the economic return from controlled clinical trials"

    • Jon Karnon
    • A. Brennan
    • J. Chilcott

    Commentary Pages: 239 - 240